These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7983749)

  • 21. Syncytium induction in primary CD4+ T-cell lines from normal donors by human immunodeficiency virus type 1 isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells.
    Todd BJ; Kedar P; Pope JH
    J Virol; 1995 Nov; 69(11):7099-105. PubMed ID: 7474129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.
    Koito A; Harrowe G; Levy JA; Cheng-Mayer C
    J Virol; 1994 Apr; 68(4):2253-9. PubMed ID: 8139010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Gram GJ; Hemming A; Bolmstedt A; Jansson B; Olofsson S; Akerblom L; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):253-61. PubMed ID: 7832633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120.
    Fu YK; Hart TK; Jonak ZL; Bugelski PJ
    J Virol; 1993 Jul; 67(7):3818-25. PubMed ID: 8510207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
    Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
    Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
    J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.
    Sattentau QJ; Moore JP; Vignaux F; Traincard F; Poignard P
    J Virol; 1993 Dec; 67(12):7383-93. PubMed ID: 7693970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
    Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.
    Hogervorst E; de Jong J; van Wijk A; Bakker M; Valk M; Nara P; Goudsmit J
    J Virol; 1995 Oct; 69(10):6342-51. PubMed ID: 7666535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.
    Schuitemaker H; Kootstra NA; de Goede RE; de Wolf F; Miedema F; Tersmette M
    J Virol; 1991 Jan; 65(1):356-63. PubMed ID: 1985204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.
    Mulligan MJ; Ritter GD; Chaikin MA; Yamshchikov GV; Kumar P; Hahn BH; Sweet RW; Compans RW
    Virology; 1992 Mar; 187(1):233-41. PubMed ID: 1736526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein.
    Dimitrov DS; Hillman K; Manischewitz J; Blumenthal R; Golding H
    J Virol; 1992 Jan; 66(1):132-8. PubMed ID: 1727475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    McKeating JA; Cordell J; Dean CJ; Balfe P
    Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.
    McKeating JA; Bennett J; Zolla-Pazner S; Schutten M; Ashelford S; Brown AL; Balfe P
    J Virol; 1993 Sep; 67(9):5216-25. PubMed ID: 7688820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.
    McKeating J; Balfe P; Clapham P; Weiss RA
    J Virol; 1991 Sep; 65(9):4777-85. PubMed ID: 1870202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.